The US Food and Drug Administration (FDA) has approved Libtayo (cemiplimab-rwlc) for the treatment of patients with metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not candidates for curative surgery or curative radiation. Libtayo is a fully human monoclonal antibody targeting the immune checkpoint receptor PD-1

(programmed cell death protein-1) and is the first and only treatment specifically

approved and available for advanced cSCC in the US. cSCC is the second most common skin cancer in the US

Libtayo is manufactured by both Regeneron and Sanofi, headquartered in Eastview, NY, and Paris, France, respectively.

Dosage/administration: The recommended dosage of Libtayo is 350 mg as an intravenous infusion over 30 minutes every 3 weeks.

Adverse effects: The most common adverse reactions (incidence ≥20%) were fatigue, rash,

and diarrhea.